Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Seeing the Full Picture: Advancing Ultra-Low Contrast PCI
Author(s): Matthias Götberg , Karim Al-Azizi , Added: 2 months ago
Dr Matthias Götberg (Skane University Hospital, SE), Dr Karim Al-Azizi (Baylor Scott & White Legacy Heart Center, US) and Prof Farrel Hellig (Sunninghill Hospital, ZA) delve into the evolving field of ultra-low contrast PCI. The faculty explore how interventional cardiologists can achieve procedural precision while significantly reducing contrast usage.Through a combination of expert… View more

Intervention
ACC 2025: EVOLUT Low Risk 5Y Outcomes
Author(s): Michael J Reardon Added: 10 months ago
ACC 2025 - EVOLUT Low-Risk findings show the Medtronic TAVR system is a safe and effective treatment for aortic stenosis vs surgical valves at five years.Dr Michael Reardon (Houston Methodist, Texas, US) joins us onsite at ACC to discuss the EVOLUT Low Risk trial (NCT02701283; Medtronic Cardiovascular), investigating the safety and effectiveness of the Medtronic TAVR system compared to surgical… View more

Intervention
Seeing the Full Picture: Advancing Ultra-Low-Contrast PCI
Author(s): Matthias Götberg , Karim Al-Azizi , Start date: Oct 30, 2025
Join Dr Matthias Götberg (Skane University Hospital, SE), Dr Karim Al-Azizi (Baylor Scott & White Legacy Heart Center, US) and Prof Farrel Hellig (Sunninghill Hospital, ZA) in this webinar as they delve into the evolving field of ultra-low contrast PCI. The faculty will explore how interventional cardiologists can achieve procedural precision while significantly reducing contrast usage.Through a… View more

Intervention
TCT 23: Four-Year Outcomes from the EVOLUT Low Risk Trial
Author(s): Michael J Reardon Added: 2 years ago
TCT 23 - In this succinct interview, we are joined by Dr Michael Reardon (Houston Methodist, US) to discuss the four-year outcomes from the EVOLUT Low-Risk Trial (NCT03635424), sponsored by Medtronic. The EVOLUT Low-risk trial is a multicenter, prospective, single-arm study which aimed to assess the procedural safety and efficacy of the Medtronic TAVR system in 150 patients with bicuspid… View more

Intervention
TCT 23: 5Y Outcomes From the PARTNER 3 Low-Risk Trial
Author(s): Martin B Leon Added: 2 years ago
TCT 23 - In this short virtual interview, we are joined by Dr Martin B Leon (Columbia University Medical Center, US) to discuss the 5-year outcomes from Edwards' PARTNER 3 low-risk trial (NCT02675114).PARTNER 3 is a randomized, prospective, multicenter trial that aimed to determine the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with severe calcific aortic… View more

Intervention
Medtronic
Author(s): Julia Grapsa , Vijay Kunadian , Stephan Windecker , et al Added: 4 months ago
The ESC Congress 2025 symposium, “Transforming the Care of Female and Low-Risk Younger Patients With Aortic Stenosis Through Guidelines” is now available on demand.Chaired by Prof Stephan Windecker (Bern University Hospital, Bern, Switzerland) and Prof Vijay Kunadian (Newcastle University, Newcastle-upon-Tyne, UK), this session explores evolving strategies to optimise care for women and younger… View more

CV Disease in Special Populations

Demographic
TAVR vs Surgery: PARTNER 3 7-Year Low-Risk Outcomes
Added: 2 months ago Source:  Radcliffe Cardiology
Long-term data from the PARTNER 3 trial show no significant differences in key clinical outcomes at 7 years between transcatheter aortic-valve replacement (TAVR) and surgical aortic-valve replacement (SAVR) for low-risk patients with severe, symptomatic aortic stenosis.¹ This extended follow-up provides crucial insights into the durability and long-term safety of both procedures in this patient… View more

Guidelines & Statements

Heart Failure
TAVI Linked to Lower 1-Year Mortality and Stroke Risk Versus SAVR in Low- to Intermediate-Risk Patients
Added: 4 months ago Source:  Transcatheter Academy
A large-scale meta-analysis suggests that for patients with severe symptomatic aortic stenosis (AS) at a low- to intermediate-surgical risk, transcatheter aortic valve implantation (TAVI) is associated with a lower risk of all-cause death or any stroke at one year compared with surgical aortic valve replacement (SAVR).¹This study was an individual participant data (IPD) meta-analysis of four… View more

Demographic

Electrophysiology & Arrhythmia
Research Area(s) / Expertise:
Job title: Professor of Vascular Medicine